Volastra Therapeutics
BiotechnologyView the employees at
Volastra Therapeutics-
Rafael Depetris Ph. D. in Structural Biology
-
New York, New York, United States
-
Top 10%
Jacqueline Gonzalez Executive Assistant-
New York, New York, United States
-
Rising Star
Celia Andreu-Agullo Director, Biomarkers, Volastra Therapeutics-
New York, New York, United States
-
Rising Star
Reka Letso Lab Ops & Management, Researcher | PhD-
New York, New York, United States
-
Rising Star
Kassoum Nacro Director of Chemistry at Volastra Therapeutics-
New York, New York, United States
-
Rising Star
Overview
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.
-